BioLineRx Ownership
| BLRX Stock | USD 3.22 0.06 1.90% |
BioLineRx |
BioLineRx Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLineRx has Price/Earnings To Growth (PEG) ratio of 0.2. The entity recorded a loss per share of 12.0. The firm last dividend was issued on the 15th of July 2019. BioLineRx had 1:40 split on the 30th of January 2025. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. For more info on BioLineRx please contact the company at 972 8 642 9100 or go to https://www.biolinerx.com.Besides selling stocks to institutional investors, BioLineRx also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BioLineRx's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BioLineRx's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BioLineRx Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of BioLineRx are currently held by insiders. Unlike BioLineRx's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BioLineRx's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BioLineRx's insider trades
BioLineRx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLineRx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLineRx backward and forwards among themselves. BioLineRx's institutional investor refers to the entity that pools money to purchase BioLineRx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Envestnet Asset Management Inc | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Cutter & Co Brokerage, Inc. | 2024-12-31 | 0.0 | Atria Wealth Solutions, Inc. | 2024-12-31 | 0.0 | Rathbone Brothers Plc | 2024-12-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | Atria Investments Llc | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Values First Advisors Inc | 2024-12-31 | 166.4 K | Rhumbline Advisers | 2024-12-31 | 43 K |
BioLineRx Outstanding Bonds
BioLineRx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLineRx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLineRx bonds can be classified according to their maturity, which is the date when BioLineRx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BioLineRx Corporate Filings
6K | 21st of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 10th of January 2025 Other Reports | ViewVerify | |
| 7th of January 2025 Other Reports | ViewVerify | |
| 27th of December 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.